Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition for curing mouth ulcer

A technology for oral ulcers and compositions, which is applied in the field of pharmaceutical compositions for the treatment of oral ulcers in humans or mammals, can solve the problems of accelerated ulcer healing, chronic toxicity, easy to produce systemic side effects, etc. Effect

Active Publication Date: 2009-02-25
天津药业集团有限公司
View PDF1 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Dexamethasone acetate can play an anti-inflammatory role, can promote the contraction of the ulcer surface, and accelerate the healing of the ulcer. However, due to the side effects of glucocorticoids, even if they are applied locally, they are prone to systemic side effects when used for a long time, that is, the hypothalamus— Inhibition of the pituitary-adrenal (HPA) axis
Moreover, according to the adhesive tablet described in this patent, dioctyl phthalate, which is harmful to the human body, is used as a plasticizer for the protective layer, and each adhesive tablet contains up to 0.8 mg of dioctyl phthalate. Although the acute toxicity of phthalate plasticizers is very small, studies have shown that phthalate plasticizers have great chronic toxicity to human health. Animal studies at home and abroad have shown that even low doses of phthalates Phthalate ester plasticizers can also be toxic to the nervous and reproductive systems of animals, especially the male reproductive system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] paste sheet

[0041] Dexamethasone acetate 0.3g

[0042] Vitamin B 12 0.05g

[0043] Carbomer 10g

[0044] Dextrin 30g

[0045] Magnesium stearate 0.03g

[0046] The protective layer

[0047] 100-55 4g

[0048] Titanium dioxide 1g

[0049] Yellow Iron Oxide 1g

[0050] Acetyl tributyl citrate (ATBC) 0.8g

[0051] Preparation Process:

[0052] Dissolve dexamethasone acetate with 5ml absolute ethanol, and vitamin B 12 Add 5ml of purified water to dissolve, add the solution of the above active ingredients to the dextrin passed through a 100-mesh sieve, mix well, then granulate through a 30-mesh sieve, dry at 60°C, granulate through a 40-mesh sieve, add 100-mesh sieve Mesh sieved carbopol and magnesium stearate are fully mixed, and then compressed with a flat punch with a diameter of 6 mm to obtain 1000 tablets, containing 0.30 mg of dexamethasone acetate and vitamin B 12 0.05 mg. the prescribed amount Dissolve L 100-55 with 95ml of 95% ...

Embodiment 2

[0054] As in the formulation of Example 1, 2 g of lidocaine hydrochloride was added to the active ingredient and dissolved in an appropriate amount of purified water, and added separately with other active ingredients. Other preparation technology is with embodiment 1

Embodiment 3

[0056] paste sheet

[0057] Dexamethasone 1g

[0058] Vitamin B 12 0.1g

[0059] Carbomer 5g

[0060] Polyvinylpyrrolidone (PVP) 3g

[0061] Dextrin 30g

[0062] Magnesium stearate 0.05g

[0063] The protective layer

[0064] 100-55 4g

[0065] Titanium dioxide 0.5g

[0066] Tributyl citrate (TBC) 0.8g

[0067] Preparation Process:

[0068] Dissolve dexamethasone with 10ml absolute ethanol, and vitamin B 12 Add 5ml of purified water to dissolve, add the solution of the above active ingredients to the dextrin passed through a 100-mesh sieve, mix well, then granulate through a 30-mesh sieve, dry at 60°C, granulate through a 40-mesh sieve, add 100-mesh sieve Mesh sieved carbomer, PVP, and magnesium stearate are fully mixed, and pressed with a flat punch with a diameter of 6 mm to obtain 1,000 tablets, containing 1 mg of dexamethasone vitamin B 12 0.1 mg. the prescribed amount 100-55 was dissolved with 95ml of 95% ethanol, added TBC and titanium diox...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition used for treating human or animal dental ulcer; the medicinal composition consists of an active component, dexamethasone, one or more medicinal salts or esters thereof, vitamin B12, and one or more medicinal inactive components that are suitable for local administration to the oral cavity.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition for treating oral ulcer of human or mammal and application thereof. Background technique: [0002] Oral ulcer is also called recurrent aphtha, is commonly called as aphthous ulcer, is a kind of common oral cavity membrane disease. Recurrent oral ulcers refer specifically to a class of unexplained, recurrent but self-limited, isolated, round or oval ulcers. It is also called recurrent aphthous ulcer (Aphthous is the meaning of "burning and ulceration" in Greek) or recurrent aphthous ulcer. Clinically, it can be divided into three types according to the size, depth and number of ulcers: recurrent mild oral ulcers, recurrent stomatitis ulcers and recurrent necrotizing mucosal periadenitis. [0003] Recurrent oral ulcers are one of the most common diseases in oral mucosal diseases. In people's life, there are almost no oral ulcers that do not occur, but some people have occasional attacks, and some p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/573A61K31/714A61K9/70A61K9/06A61P1/02
Inventor 郝于田张乐张其婉李宏铃马晓勇陈松
Owner 天津药业集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products